The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...

DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

The US Food and Drug Administration (FDA) has approved UK pharma major GSK’s Blenrep belantamab mafodotin-blmf) in ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...